A fascinating deep dive into the discovery, use and implications of a revolutionary new treatment
Few aspects of being human have generated more judgment, scorn and condemnation than a person’s size, shape and weight – particularly if you happen to be female. As late as 2022, the Times’s columnist Matthew Parris published a column headlined “Fat shaming is the only way to beat the obesity crisis” in which he attributed Britain’s “losing battle with fat” to society’s failure to goad and stigmatise the overweight into finally, shamefacedly, eating less. The tendency to equate excess weight with poor character (and thinness with grit and self-control) treats obesity as a moral as well as physical failing – less a disease than a lifestyle choice.
One of the great strengths of Reuters journalist Aimee Donnellan’s first book is its insistence on framing the discovery of the new weight-loss drugs within the fraught social and cultural context of beauty norms, body image and health. For those who need them, weekly injections of Ozempic, Wegovy or Mounjaro can be revolutionary. Yet for every person with diabetes or obesity taking the drugs to improve their health, others – neither obese nor diabetic – are obtaining them to get “beach-body” ready, fit into smaller dresses, or attain the slender aesthetic social media demands of them. Small wonder some commentators have likened the injections to “an eating disorder in a pen”.
Continue reading...
